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Abstract 
The oncogenic form of Ras signaling is associated with 30% of human cancers, including 
90% of pancreatic tumors, was first genetically characterized in Drosophila.  Subsequent genetic 
screens have identified many additional genes in the pathway. To identify novel candidates, we 
have conducted an in vitro screen using an inducible Ras oncogene in Drosophila tissue culture 
cells developed in our lab. This conditional cell line requires the control of oncogenic RasV12 
expression induced by GeneSwitch-Gal4 (GSR) for proliferation. Using RNAseq analysis, 363 
gene transcripts were identified that were upregulated two-fold or greater by oncogenic RasV12 
expression.  Of these, 91 candidate genes were tested further for functional analysis using RNAi 
in flies.  Ubiquitous knock-down of 38 target genes caused death or decreased viability of the 
organism, suggesting their essential role, and depletion of another gene caused a wing phenotype. 
As the Ras pathway is known to play an important role in wing-vein patterning, I carried out tissue-
specific knock-downs in the wing.  I am characterizing further three genes whose depletion results 
in the most robust wing venation defects. Knock-down of G protein gamma 30A (Gγ30A), a G-
protein subunit, in the wing causes extra vein phenotypes, consistent with a negative Ras pathway 
regulator.  Knock-down of CG12009, a chitin-binding protein, and CG31689, an ABC transporter, 
in the wing causes loss of vein phenotypes, consistent with positive Ras pathway regulators. 
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Introduction 
The conserved Ras protein, present in all animals, responds to growth factor signaling 
between cells.  Ras is a membrane-bound G protein that functions as a molecular switch that 
converts signals from the cell membrane to the nucleus to control cell growth, differentiation and 
survival. Its mutated form is permanently active and behaves as an oncogene; cells will 
continuously grow and divide, giving rise to tumors.  Oncogenic Ras is associated with 30% of 
human cancers, including 90% of pancreatic tumors.  For this reason, it is imperative to identify 
all of the components of the Ras pathway, as these components could be used as therapeutic targets.  
The Ras pathway was first characterized in Drosophila (Simon et al. 1991) and C. elegans (Han 
and Stenberg 1990). Subsequent genetic screens have identified many additional components of 
the pathway validated in mammals. Given the high degree of conservation of core signaling 
pathways, and that genetic analysis can be carried out rapidly in Drosophila, this makes 
Drosophila a good model system to gain knowledge of the Ras pathway and apply it in mammals. 
My goal is to identify novel Ras pathway components that will not only better our knowledge of 
the pathway but also identify potential candidates for targeted therapy.   
The Ras protein itself is a poor target for therapy (Downward, J. 2003 and Gysin, S. et al. 
2011), so finding downstream Ras effectors and other targets involved in Ras protein synthesis 
will be of great importance.  To this aim, our lab has developed a conditional Drosophila cell line 
in which cell growth and proliferation are under the control of an inducible form of oncogenic 
RasV12. The cell line takes advantage of the GeneSwitch-Gal4 system developed by the Keshishian 
group (Osterwalder et al. 2001 and Nicholson et al. 2008), in which RasV12 expression can be 
induced by the RU486 drug in Drosophila tissue culture cells. In the presence of the RU486 drug, 
Gal4 activation induces RasV12 and GFP expression. Without the drug, Gal4 is not activated and 
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cells lack RasV12 and GFP expression.  The system successfully lead to the establishment of 
primary cell cultures with Act5C-GeneSwitch-Gal4 driving expression of UAS-RasV12 and UAS-
GFP in the presence of RU486 (Figure 1).  Work in the lab has shown that cell proliferation is 
tightly controlled by this system, and only primary cultures treated with RU486 reached 
confluence and gave rise to continuous cell lines.  Two independent cell lines (GSR2 and GSR6) 
were established that show drug-dependent proliferation (Figure 1A).  Cells were incubated 
without RU486 for 8 days and then the drug was reintroduced, causing cell proliferation (Figure 
1A).  This shows that the GSR cells are still alive, yet in a dormant state in the absence of the drug, 
and depend on RasV12 expression for proliferation. FACS analysis of the cell cycle profile of the 
GSR cells in the absence and presence of RU486 found that GSR cells without RU486 accumulate 
in G0/G1 phase, but remain viable and quickly reenter the cell cycle upon RU486 reintroduction 
(Figure 1B).  
Figure 1: (A) GSR cells (GSR2 – black circles, GSR6 – white circles) cultured in the presence of RU486 
proliferate (blue curve). GSR cells cultured without RU486 do not proliferate (red curve), but these same 
cells start to proliferate again after RU486 is reintroduced (yellow curve).  (A. Heinaman, unpublished) 
(B) Control cells with (i) or without RU486 (ii) displayed different cell cycle profiles (both cultures had 
similar numbers of cells). When RU486 was added back to the cultures the cells entered the cell cycle and 
more cells in G
2
/M were observed (iii and iv). # = % each stage. (Simcox Lab, unpublished) 
A 
B 
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A comparative analysis of gene expression in induced and non-induced cells was 
performed in the lab using RNAseq.  363 genes were found to upregulated upon RasV12 induction 
in both the GSR2 and GSR6 cells. I conducted a selective genetic screen to validate these Ras-
responsive gene candidates using reverse genetics.  RNAi screens in Drosophila have proven 
valuable to identify novel components of signaling pathways (Jia et al. 2015 and Luo et al. 2015).  
Often, the Drosophila wing is used as a model for studying signaling, as the Egfr/Ras, Hh, Dpp, 
Wingless, and Notch signaling pathways all are required for proper vein patterning (reviewed in 
Blair 2007).  For the Ras pathway, vein loss phenotypes are indicative of reduced Ras signaling 
and extra vein phenotypes are indicative of increased Ras signaling (Roch et al. 2002). The wing 
is also dispensable for viability and has a strict vein pattern that can easily be scored for alterations.  
Previous studies in our lab have successfully used the fly wing to characterize new regulators of 
the Egfr signaling (Butchar et al. 2012 and Jacobsen et al., 2006). In fact, I have identified three 
genes that caused robust venation defects: Gγ30A, a potential negative Ras pathway regulator and 
CG12009 and CG31689, potential positive Ras pathway regulators. 
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Materials and Methods 
Fly stocks:  
The following gene alleles and transgenes were used: Dp(1;3)DC141, Dp(1;3)DC142, 
Dp(1;3)DC143, Dp(1;3)DC144, ap-Gal4, UAS-Egfr, UAS-yki, UAS-GFP, CG4096EPgy2, EgfrElp, 
Ras85De1B, UAS-Dcr-2, Act5C-Gal4, en-Gal4, 69B-Gal4, 71B-Gal4, and vn-Gal4 (Austin et al. 
2015). 
For the screen in adult wings, a complete list of transgenic RNAi stocks obtained from the Harvard 
TRiP (Transgenic RNAi Project) and VDRC (Vienna Drosophila Research Center) collections is 
available in Appendix 2. 
RNAseq of GSR cells:  
Two runs of RNAseq were performed in the lab in both the presence and absence of RU486 for 
two independent inducible RasV12 cell lines (GSR2 and GSR6) as well in a constitutive control 
line (Ras7).  The RNAseq was performed on cells after 5 days in presence or absence of RU486.  
Expression data from the Ras7 line was used to eliminate transcripts upregulated due to the 
presence of RU486 alone. 
Analysis of CG4096 muatation generated by CRISPR/Cas9 targeting: 
Cells expressing Cas9 via integration by RMCE (Recombinase-Mediated Cassette Exchange) were 
transfected with plasmid pU6-GuideRNA.CG4096 which contains the RNA targeting sequence 
against CG4096 or with plasmid pU6-GuideRNA.SC which contains a control scrambled 
sequence.  Genomic DNA from the cells was isolated 36h post-transfection.  The region flanking 
the presumed CRISPR/Cas9 target site was amplified using Phusion (NEB)-mediated PCR and 
primers FP.CG4096.PCR and RP.CG4096.PCR.  Mutations were detected using the PCR product 
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and a Surveyor Mutation Detection Kit (Transgenomic) by following the protocol that cuts at 
mismatched sequences resulting from CRISPR/Cas9-induced deletions or insertions. 
(Manivannan, S. N., et al. 2015) 
Primers: 
Primers used in this study, shown in the 5’-to-3’ orientation: 
CG4096CRISPRsenseNOPAM: CTTCGGTGGCGTACGTCCGCTTTA 
CG4096CRISPRantiNOPAM: AAACTAAAGCGGACGTACGCCACC 
ScCRISPRsense: CTTCCCGGTTTTATGGATCCGGCG 
ScCRISRPanti: AAACCGCCGGATCCATAAAACCGG 
FP.CG4096.PCR: AAACTAAAGCGGACGTACGCCACC 
RP.CG4096.PCR: GGTGGCGCTCCACCACCAG 
W.CRISPRsenseNOPAM: CTTCGGCACAATACGACATCTTT 
W.CRISPRantiNOPAM: AAACAAAGATGTCCATATTGTGCC 
Injections: 
CG4096EPgy2 embryos were collected based on the protocol from Kiehart et al. 2000. The injection 
mixture was prepared with 10X injection buffer (1mM Sodium Phosphate Buffer pH 6.8, 50mM 
KCl), green food dye, nuclease-free water and the following plasmids: Actin5C-Gal4 (200 ng/µL), 
pU6-GuideRNA.CG4096 (150 ng/µL), pU6-GuideRNA.w (150 ng/µL), and pUAST-Cas9-SV40 
(300 ng/µL). 
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Immunohistochemistry: 
Late third instar wing discs were stained for actin using Rhodamine phalloidin (ThermoFisher 
Scientific) using methods describe in Copppey et al. (2008). Rhodamine phalloidin was used at 
1:1000 dilution and samples were mounted in ProLong® Gold Antifade Mountant with DAPI 
(ThermoFisher Scientific). 
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Results and Discussion 
RNAseq analysis of inducible RasV12 GSR cells identifies known and candidate Ras pathway 
genes 
Based on the success of previous reverse genetic screens in our lab that generated new Egfr 
regulators like CG4096, I constructed a similar experimental methodology (Figure 3) to identify 
new Ras pathway interactors. RNAseq was performed on the GSR cells in order to identify genes 
induced in response to RasV12 expression. Comparative RNAseq data analysis found a total of 363 
gene transcripts that were upregulated by two-fold or greater when RasV12 expression was induced. 
I selected the top 98 upregulated genes for bioinformatics analysis, and complete GO information 
of the 98 genes is provided in Appendix 1. Expression profiles of a subset of genes selected for 
functional analyses can be seen in Figure 2.  
Figure 2: Heat map of a subset of candidate genes upregulated in GSR+ cells 
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RNAseq of GSR cells 
363 Genes 
Bioinformatics analysis 
98 Genes 
Known Ras Pathway Components 
4 Genes 
No Transgenic Lines Available 
3 Genes 
Ubiquitous Knock-down 
Act5C-Gal4 
91 Genes 
Tissue-specific Knock-down 
vn-Gal4 
40 Genes 
Tissue-specific Knock-down 
en-Gal4, 69B-Gal4, 71B-Gal4 
9 Genes 
Characterization of 
Genetic Interactions  
3 Genes 
Figure 3:  Experimental flow chart for functional analysis of candidate genes 
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Functional analysis of candidate genes using ubiquitous RNAi-induced knock-down 
Of the 98 most upregulated genes, three genes are known components of the Ras pathway: 
Ras85D, branchless (Gabay, L. et al. 1997), and CG4096 (Butchar et al. 2012).  One gene, 
wingless, has been previously shown to interact with the Ras signaling pathway (Carmena, A. et 
al. 2006). Three genes lacked available transgenic lines (CG4914, CG34194, CG9165).  I therefore 
conducted a functional analysis of the remaining 91 genes using RNAi. RNAi transgenes were 
ubiquitously expressed using Act5C-Gal4. Silencing of 40 genes affected viability – lethality (38), 
low viability (1) – or generated a held out wings phenotype (1) (Figure 4). Crosses were conducted 
at 29°C to enhance Gal4 activity in order to increase RNAi effects (Dietzl G. et al. 2007).  
Appendix 2 lists results of all the crosses conducted for both ubiquitous and tissue-specific knock-
downs of the candidate genes. 
 
Figure 4: A breakdown of the RNAi 
phenotypes seen from Act5C-Gal4 
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Recently, it has been shown that approximately 25% of transgenic lines from the VDRC 
KK RNAi collection cause false-positive enhancement of the gene tiptop (tio) due to an insertion 
into the tio 5’ UTR (Vissers et al. 2016; Green et al. 2014). tio is a transcription factor in Hippo 
pathway, which controls tissue growth (Vissers et. al. 2016). This enhancement results in in pupal 
lethality when broadly expressed and in wing phenotypes when expressed by wing-specific Gal4 
lines (Vissers et al. 2016; Green et al. 2014).  I found that 6/33 (18%) of the KK lines used in this 
study were indeed affected by this false positive enhancement, showing pupal lethality in Act5C-
Gal4,  small uninflated wings in 69B-Gal4, and smaller wings in 71B-Gal4.  With 71B-Gal4, I 
could still screen for venation defects in these candidates, however none were observed with any 
of these candidates. 
Tissue-specific knock-down reveals three candidate genes involved in wing development 
To further refine the role of the 39 genes for which ubiquitous knock-down was lethal, I 
conducted tissue-specific knock-down mediated by several Gal4 lines.  First, I used vn-Gal4 to 
inhibit gene expression in the same expression pattern as vn, an Egfr ligand. The vn-Gal4 driver 
contains Gal4 inserted into the 2nd exon of the vn gene, creating a loss of function allele of vn 
(Austin et al. 2015). vn-Gal4 provides a sensitized genetic background I took advantage of to 
identify genes in the Egfr/Ras pathway. RNAi depletion driven by vn-Gal4 caused phenotypes in 
9 of 39 genes (Table 1). A compilation of all crosses is shown in Appendix 2. I further selected 
candidates that showed wing-vein phenotypes with other Gal4 drivers as well (en-Gal4, 69B-Gal4, 
and 71B-Gal4).  We chose Gal4 drivers for their property to silence candidate genes in various 
compartments of the adult wing and at different times of wing development (Figure 5).  Crosses 
were first carried out at 29°C for the strongest effect, and were repeated at 17°C and 25°C when 
knock-down was lethal at 29°C.  
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Figure 5:  (A) Time-specific expression pattern in the wing disc of the Gal4 lines used, 
with larval stage indicated above the chart (B-E) Expression pattern of the Gal4 drivers 
shown in the adult wing 
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Based on wing phenotypes with vn-Gal4 and other Gal4 lines, we chose 3 genes for further 
investigation (Figure 6). Knock-down of Gγ30A caused lethality when directed by vn-Gal4 and a 
consistent extra-vein phenotype with the other three Gal4 drivers.  Several genes showed a loss of 
the anterior cross vein with vn-Gal4, which is sensitive to Egfr signaling (Clifford and Schupbach 
1989 and Schnepp et al. 1996).  I focused only on CG12009 and CG31689 for further analysis as 
these genes show vein loss with en-Gal4 as well.  
Table 1: Genes showing phenotypes with vn-Gal4 
Gene Human Ortholog Molecular Function 
RNAi Phenotype 
Act5C-Gal4
RNAi Phenotype 
vn-Gal4
RNAi Phenotype with 
Other Gal4 Lines
Gγ30A
guanine nucleotide binding 
protein gamma 13
Protein 
heterodimerization 
activity, signal transducer 
activity
Lethal Lethal
Extra vein: en-Gal4, 
69B-Gal4, 71B-Gal4
SP1029 Alanyl aminopeptidase
aminopeptidase activity, 
metallopeptidase activity, 
zinc ion binding
Lethal Lethal Extra vein: en-Gal4
CG31689
ATP binding cassette 
subfamily G member 1
ATPase activity, coupled 
to transmembrane 
movement of substances
Lethal Loss of vein Loss of vein: en-Gal4
CG8483 GLI pathogenesis related 1 unknown Lethal Loss of vein Loss of vein: en-Gal4
CG34396
potassium two pore 
domain channel subfamily 
K member 18
open rectifier potassium 
channel activity
Lethal Loss of vein None
ccn
connective tissue growth 
factor
growth factor activity Lethal Loss of vein Loss of vein: en-Gal4
CG12009
Fibrous sheath CABYR 
binding protein
chitin binding Lethal Loss of vein Loss of vein: en-Gal4
CG32512
transmembrane protein 
205
unknown Lethal Lethal
Lethal: 69B-Gal4,   
71B-Gal4
loopin-1 leucine aminopeptidase 3
aminopeptidase activity, 
manganese ion binding, 
metalloexopeptidase 
activity
Lethal Lethal None
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Gγ30A: Gγ30A encodes a G protein gamma subunit of unknown function.  Gγ30A has been shown 
to dimerize with Gβ76C in the cytoplasm and to be involved in the Drosophila visual transduction 
in the compound eye (Schulz et al. 1999).  RNAi silencing of Gγ30A resulted in lethality with vn-
Gal4 and in extra vein phenotypes that were indistinguishable with en-Gal4, 69B-Gal4, and 71B-
A B C 
D E 
G H 
I J 
Wild-type 69B-Gal4>vn
RNAi
 Act5C-Gal4>CG4096
RNAi
 
69B-Gal4>Gγ30A
RNAi
 71B-Gal4>Gγ30A
RNAi
 en-Gal4>Gγ30A
RNAi
 
en-Gal4>CG12009
RNAi
 vn-Gal4>CG12009
RNAi
 
vn-Gal4>CG31689
RNAi
 en-Gal4>CG31689
RNAi
 
F 
Figure 6: Wing phenotypes caused by RNAi in restricted domains 
(A) Wild-type wing (B) Control: vn is a known positive regulator of Ras signaling and shows wing 
vein loss when knocked-down (C) Control: CG4096 is a known negative regulator of Ras signaling 
and shows extra wing veins when knocked-down (D-F) Knock-down of Gγ30A causes extra vein 
phenotypes (G-H) Knockdown of CG12009 causes loss of vein phenotypes (I-J) Knock-down of 
CG31689 causes loss of vein phenotypes 
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Gal4 (Figure 6 D-D”).  These extra vein patterns are also similar to those seen in EgfrElp, which is 
a hypermorphic allele of Egfr that causes extra vein phenotypes.  The observed extra vein 
phenotypes suggest that Gγ30A may be a negative regulator of Ras signaling. The human ortholog 
of Gγ30A, guanine nucleotide binding protein gamma 13 (GNG13) dimerizes with Gβ1 and Gβ3 
and activates two phospholipases (PLCβ1 and PLCβ3) (Poon et al. 2009).  PLCβ1 has been shown 
to activate protein kinase C (PKC) and activate raf through a p21/ras-independent mechanism (Van 
Biesen et al. 1996). Restoration of PLCβ3 was shown to inhibit growth rate and neoplasticity in 
neuroendocrine tumorigenesis (Stalberg et al. 1999).  Thus, it would be important to conduct 
further experiments to understand the role of Gγ30A in Drosophila. 
CG12009: CG12009 is an uncharacterized gene containing a chitin binding domain and is 
predicted to localize in the extracellular region.  Little is known about its human ortholog, FSCB 
(Fibrous Sheath CABYR binding protein). FSCB has been shown to be phosphorylated by protein 
kinase A and is involved in fibrous sheath biogenesis (Li et al. 2007).  In flies, knock-down of 
CG12009 causes loss of the anterior cross vein (ACV) and parts of the 3rd longitudinal vein when 
directed by vn-Gal4 (Figure 6 E’) and loss of the ACV when directed by en-Gal4 (Figure 6 E).  
These loss of vein phenotypes suggests that CG12009 may be a positive regulator in Ras signaling. 
Ongoing analyses aim to test this hypothesis. 
CG31689: CG31689 is another uncharacterized gene containing domains predicted to be involved 
in ATPase activity coupled to transmembrane movement of substances.  Its human ortholog 
ABCG1 (ATP-binding cassette transporter G1) is a member of the ABC transporter family and 
regulates cellular cholesterol homeostasis by effluxion of excess cholesterol from cells to high-
density lipoportein (HDL) particles for elimination of cholesterol from the body (Kennedy et al. 
2005 and Wang et al. 2004).  In my RNAi screen in Drosophila, CG31689 depletion resulted in 
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the loss of the ACV with vn-Gal4 and a more severe vein and wing size losses with en-Gal4 (Figure 
6 F-F’).  These loss of vein phenotypes suggest that CG31689 plays a positive role in vein 
patterning and potentially in Ras signaling.  Reports point at a role of ABCG1 in several types of 
cancers (El Roz et al. 2012 and Sag et al. 2015).  Recently, loss of ABCG1 in mice was shown to 
impair tumor growth and increases animal survival through the modulation of macrophage survival 
within the tumor microenvironment (Sag et al. 2015).  Further analysis on how ABCG1 and 
cholesterol metabolism affect tumor immunity could lead to new therapeutic approaches.   
Further interaction analysis to link candidates to the Ras pathway 
 While it is evident that Gγ30A, CG12009, and CG31689 are involved in wing vein 
patterning, further analysis is needed to link these genes to the Ras pathway; a model of the 
predicted interactions between the candidates and Ras is shown in Figure 7. I am proposing some 
experiments that will characterize the genetic interactions between these genes and the Ras 
pathway.   
First, in vivo genetic interactions will be determined by testing the knock-down of the 
candidate gene in two different mutant backgrounds in flies: EgfrElp (a hypermorphic mutant of 
Egfr) and Ras85De1B (a null mutant of Ras). Our expectation is that in the EgfrElp background will 
enhance the extra vein phenotype of a negative regulator (Gγ30A) and eliminate the loss of vein 
phenotype of a positive regulator (CG12009 or CG31689). If genetic interactions exist between 
the candidate and the Ras, the heterozygous Ras85De1B background would enhance the loss of vein 
phenotype of a positive regulator or eliminate the extra vein phenotype of a negative regulator. 
 A second approach to further characterization of the candidates will use RNAi-induced 
knock-down in cell culture. Wts cells established in the lab are particularly suited to study Egfr/Ras 
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signaling components: these cells are epithelial in nature, and compared to commonly used 
Dosophila cell lines (S2 and Kc), Wts cells express the core Egfr pathway genes at much higher 
levels (Figure 8). This provides a good system to test alterations in Egfr/Ras signaling.  After 
conducting the knock-downs, I will test for changes in dp-ERK levels by immunoblot analysis.  
ERK is phosphorylated when Ras is activated (Figure 9), so if levels of dp-ERK change after 
knock-down of a candidate gene, that gene is a component of the Ras signaling pathway. 
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Figure 8: Expression levels of EGFR pathway genes in Wts cells 
compared to other Drosophila cell lines determined by microarray 
analysis. (Simcox Lab, unpublished) 
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GO classification of upregulated Ras-responsive genes 
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Gene Name Human Ortholog Molecular Function Biological Process 
Major heat 
shock 70 kDa 
protein Bbb 
heat shock 70kDa protein 
1A; heat shock 70kDa 
protein 1B 
heat shock-mediated 
polytene chromosome 
puffling, response to heat, 
response to hyperoxia 
protein folding, protein 
complex assembly, response 
to stress 
Ecdysone-
inducible gene 
L3 
lactate dehydrogenase A-like 
6A 
L-lactate dehydrogenase 
activity 
glycolysis, oxidation-
reduction process, cellular 
carbohydrate metabolic 
process, tricarboxylic acid 
cycle 
branchless fibroblast growth factor 16 
fibroblast growth factor 
receptor binding 
activation of MAPK activity 
CG4914 protease, serine, 33 
serine-type endopeptidase 
activity 
proteolysis 
CG15731 loricrin Unknown Unknown 
CG9416 
endoplasmic reticulum 
metallopeptidase 1 
peptidase activity proteolysis 
CG14968 
family with sequence 
similarity 43, member B 
protein binding, receptor 
binding 
apoptotic process, immune 
system process 
CG8483 
C-type lectin domain family 
18, member A 
Unknown Unknown 
UPF0670 
protein 
chromosome 8 open reading 
frame 55 
Unknown Unknown 
Ecdysone-
inducible gene 
L2 
cell adhesion molecule 2 
insulin-like growth factor 
binding 
determination of adult 
lifespan, negative and 
positive regulation of insulin 
receptor signaling pathway, 
CG8277 
eukaryotic translation 
initiation factor 4E family 
member 1B 
eukaryotic initiation factor 
4G binding, protein binding, 
RNA 7-methylguanosine 
cap binding, translation 
initiation factor activity 
autophagic cell death, 
salivary gland cell 
autophagic cell death, 
translational initiation 
 27 
 
quail villin-like 
actin binding, calcium ion 
binding 
actin filament organization, 
imaginal disc-derived wing 
hair organization, ovarian 
nurse cell to oocyte transport 
kin of irre 
nephrosis 1, congenital, 
Finnish type (nephrin) 
Unknown 
compound eye 
morphogenesis, garland 
nephrocyte differentiation, 
homophilic and heterophilic 
cell adhesion 
Probable 
mitochondrial 
import inner 
membrane 
translocase 
subunit Tim17 3 
translocase of inner 
mitochondrial membrane 17 
homolog A (yeast) 
Unknown 
cellular process, 
mitochondrial and protein 
transport 
G protein 
gamma30A 
guanine nucleotide binding 
protein (G protein), gamma 
13 
protein heterodimerization 
activity, GTPase activity, 
signal transducer activity 
cellular response to carbon 
dioxide, phototransduction 
Ras oncogene at 
85D 
neuroblastoma RAS viral (v-
ras) oncogene homolog 
GTPase activity, protein 
binding 
border follicle cell migration, 
cell proliferation, cell fate 
determination 
SoxNeuro sex determining region Y 
chromatin DNA binding, 
protein binding, RNA 
polymerase II distal 
enhancer sequence-specific 
DNA binding transcription 
factor activity 
axon guidance, (central) 
nervous system development 
CG13838 
chromosome 9 open reading 
frame 16 
unknown unknown 
CG34194 
chromosome 14 open reading 
frame 147 
unknown unknown 
Nidogen nidogen 2 (osteonidogen) calcium ion binding cell-matrix adhesion 
 28 
 
Probable 2-
oxoglutarate 
dehydrogenase 
E1 component 
DHKTD1 
homolog, 
mitochondrial 
dehydrogenase E1 and 
transketolase domain 
containing 1 
Unknown Unknown 
wunen-2 
phosphatidic acid 
phosphatase type 2C 
lipid phosphatase and 
transporter/pyrophosphatase 
activity 
germ cell development, 
migration, programmed cell 
death, and repulsion, 
dephosphorylation, 
phospholipid metabolic 
process 
CG7432 protease, serine 27 
serine-type endopeptidase 
activity 
proteolysis 
CG9411 
proline-rich protein BstNI 
subfamily 1; proline-rich 
protein BstNI subfamily 2; 
proline-rich protein BstNI 
subfamily 4 
unknown unknown 
stall 
ADAM metallopeptidase 
with thrombospondin type 1 
motif, 13 
metallopeptidase activity, 
protein binding, serine-type 
endopeptidase inhibitor 
activity, zinc ion binding 
proteolysis, cell-cell 
adhesion and cell 
communication, regulation 
of catalytic activity, ovarian 
follicle development 
Glyceraldehyde 
3 phosphate 
dehydrogenase 
2 
glyceraldehyde-3-phosphate 
dehydrogenase-like 6; 
hypothetical protein 
LOC100133042; 
glyceraldehyde-3-phosphate 
dehydrogenase 
catalytic activity, 
oxidoreductase activity 
glycolysis 
minidiscs 
solute carrier family 7, 
(cationic amino acid 
transporter, y+ system) 
member 11 
amino acid transmembrane 
transporter activity 
amino acid transmembrane 
transport, leucine import 
CG32512 transmembrane protein 205 unknown unknown 
 29 
 
wingless 
wingless-type MMTV 
integration site family, 
member 4 
receptor binding, protein 
binding, extracellular matrix 
binding 
cell communication, cell 
differentiation, regulation of 
biological process, nervous 
system development, many 
cells differentiation and 
development (not all listed 
here) 
CG18480 
leucine rich repeat containing 
33 
receptor activity 
immune system process, cell 
communication, cell-cel 
adhesion, visual perception 
CG14309 heparanase 2 
hydrolase activity, acting on 
glysosyl bonds 
Unknown 
CG31092 
low density lipoprotein 
receptor-related protein 8, 
apolipoprotein e receptor 
calcium ion binding, low-
density lipoprotein receptor 
activity 
neuron projection 
morphogenesis 
CG4438 
PDGFA associated protein 1; 
similar to PDGFA associated 
protein 1 
Unknown Unknown 
CG10859 
dynein, axonemal, 
intermediate chain 2 
ATPase activity- coupled, 
motor activity, structural 
constituent of cytoskeleton 
microtubule-based 
movement, cellular 
component morphogenesis, 
RNA localization 
Farnesyl 
pyrophosphate 
synthase 
farnesyl diphosphate 
synthase (farnesyl 
pyrophosphate synthetase, 
dimethylallyltranstransferase, 
geranyltranstransferase) 
dimethylallyltranstransferase 
activity, 
geranyltranstransferase 
activity 
wing disc development, 
germ cell migration, farnesyl 
diphosphate biosynthetic 
process, isoprenoid 
biosynthetic process 
CG11153 
SRY (sex determining region 
Y)-box 6 
sequence-specific DNA 
binding transcription factory 
activity 
transcription and regulation 
of transcription from RNA 
polymerase II promoter 
 30 
 
Heparan sulfate 
3-O 
sulfotransferase-
B 
heparan sulfate 
(glucosamine) 3-O-
sulfotransferase 3A1 
[heparan sulfate]-
glucosamine 3-
sulfotransferase 1 activity 
morphogenesis of chaeta, 
compound eye, and imaginal 
disc-derived leg and wing 
(more biological processes 
not listed here) 
CG34392 
Rap guanine nucleotide 
exchange factor (GEF) 4 
cAMP-dependent protein 
kinase regulator activity, 
Rap guanyl-nucleotide 
exchange factor activity, 
catalytic activty, small 
GTPase regulator activity, 
protein binding 
regulation of Rap protein 
signal transduction, 
metabolic process, mitosis, 
cell communication, 
regulation of catalytic 
activity 
CG31689 
ATP-binding cassette, sub-
family G (WHITE), member 
4 
ATP binding, ATPase 
activity, coupled to the 
transmembrane movement 
of substances, transporter 
activity 
Unknown 
tenectin 
A kinase (PRKA) anchor 
protein 12 
integrin binding 
morphogenesis of imaginal 
disc-derived wing and 
imaginal disc-derived male 
genitalia, embryonic hindgut, 
and epithelial tube; 
regulation of tube diameter 
CG12009 
fibrous sheath CABYR 
binding protein 
chitin binding chitin metabolic process 
CG11652 
DPH1 homolog (S. 
cerevisiae) 
unknown 
phagocytosis, peptidyl-
diphthamide biosynthetic 
process from peptidyl-
histidine 
CG34396 
potassium channel, 
subfamily K, member 18 
voltage-gated potassium 
channel activity 
sytem process, cation 
transport, potassium ion 
transmembrane transport 
pathetic 
solute carrier family 36 
(proton/amino acid 
symporter), member 3 
amino acid transmembrane 
transporter activity 
growth and growth 
regulation, intracellular 
protein and peroxisomal 
transport 
 31 
 
CG16869 
angiotensin I converting 
enzyme (peptidyl-dipeptidase 
A) 1 
NOT metallopeptidase or 
peptidyl-dipeptidase activity 
activity 
proteolysis 
CG15286 
potassium channel 
modulatory factor 1 
zinc ion binding 
no information found on 
Flybase or Panther 
nuclear export 
factor 4 
nuclear RNA export factor 1 Unknown RNA export from nucleus 
CG34107 
chromosome 9 open reading 
frame 116 
Unknown unknown 
Enolase enolase 1, (alpha) 
magnesium ion binding, 
catalytic activity, 
phosphopyruvate hydratase 
activity 
glycolysis 
CG32238 
tubulin tyrosine ligase-like 
family, member 1 
tubulin-tyrosine ligase 
activity 
C-terminal protein-
tyrosinylation, protein 
polyglutamylation 
Probable 
cytochrome 
P450 28d1 
cytochrome P450, family 3, 
subfamily A, polypeptide 4 
electron carrier activity, 
heme binding, iron ion 
binding, oxidoreductase 
activity, acting on paired 
donors, with incorporation 
or reduction of molecular 
oxygen 
oxidation-reduction process 
CG34372 
G protein-coupled receptor 
179 
G-protein coupled receptor 
activity 
G-protein coupled receptor 
signaling pathway 
CG18173 
phosphatidylinositol glycan 
anchor biosynthesis, class W 
transferase activity, 
transferring acyl groups 
GPI anchor biosynthetic 
process 
CG13320 
Usher syndrome 1G 
(autosomal recessive) 
Unknown Unknown 
no extended 
memory 
glutaminase 2 (liver, 
mitochondrial) 
carbon-monoxide oxygenase 
activity, 
imaginal disc-derived wing 
morphogenesis, locomotory 
behavior, memory 
 32 
 
CG15478 MAX binding protein 
sequence-specific DNA 
binding transcription factor 
activity, 
regulation of transcription 
from RNA polymerase II 
promoter 
CG3777 
mucin 17, cell surface 
associated 
Uknown 
proteolysis 
lysosomal transport 
intracellular protein transport 
Regulator of G-
protein 
signalling 7 
regulator of G-protein 
signaling 6 
GTPase activator activity, 
signal transducer activity 
intracellular signal 
transduction, regulation of 
G-protein coupled receptor 
protein signaling pathway, 
termination of G-protein 
coupled receptor signaling 
pathway 
Multiple 
inositol 
polyphosphate 
phosphatase 1 
multiple inositol 
polyphosphate histidine 
phosphatase, 1 
acid phosphatase activity, 
phosphoprotein phosphatase 
activity 
Uknown 
centaurin 
gamma 1A 
ArfGAP with GTPase 
domain, ankyrin repeat and 
PH domain 4; ArfGAP with 
GTPase domain, ankyrin 
repeat and PH domain 6 
zinc ion binding, GTP 
binding, ARF GTPase 
activator activity 
small GTPase mediated 
signal transduction, 
regulation of ARF GTPase 
activity 
CG6330 uridine phosphorylase 2 
uridine phosphorylase 
activity 
gravitaxis, nucleoside 
metabolic process, 
nucleotide catabolic process 
CG16957 
progesterone receptor 
membrane component 1 
heme binding   
CG4415 
NAC alpha domain 
containing 
unfolded protein binding protein targeting 
CG32183 
WNT1 inducible signaling 
pathway protein 3 
growth factor activity neurogenesis 
yolkless 
epidermal growth factor 
(beta-urogastrone) 
calcium ion binding, 
vitellogenin receptor activity 
vitellogenesis, oogenesis 
 33 
 
CG5002 
solute carrier family 26, 
member 11 
transporter activity, high 
affinity sulfate 
transmembrane transporter 
activity 
sulfate transport 
CG11546 
GIPC PDZ domain 
containing family, member 3 
G-protein alpha-subunit 
binding 
locomotion involved in 
locomotory behavior, 
establishment of planar 
polarity, determination of 
adult lifespan 
Triose 
phosphate 
isomerase 
TPI1 pseudogene; 
triosephosphate isomerase 1 
triose-phosphate isomerase 
activity 
response to mechanical 
stimulus, neurological 
system process, 
determination of adult 
lifespan 
lethal (3) 02640 
hydroxymethylbilane 
synthase 
hydroxymethylbilane 
synthase activity 
tetrapyrrole biosynthetic 
process, peptidyl-
pyrromethane cofactor 
linkage 
CG4096 
ADAM metallopeptidase 
with thrombospondin type 1 
motif, 10 
zinc ion binding, 
metalloendopeptidase 
activity 
negative regulation of 
epidermal growth factor 
receptor signaling pathway, 
proteolysis 
Netrin-B laminin, alpha 4 unknown 
axon guidance, dendrite 
guidance, glial cell 
migration,salivary gland 
boundary specific 
CG34420 dipeptidase 1 (renal) dipeptidase activity proteolysis 
CG15556 
G protein-coupled receptor 
113 
G-protein coupled receptor 
activity 
G-protein coupled receptor 
signaling pathway 
Wnt oncogene 
analog 2 
wingless-type MMTV 
integration site family, 
member 3A 
frizzled binding, receptor 
binding 
open tracheal system 
development, muscle organ 
development, axon 
extension, negative 
regulation of transcription 
from RNA polymerase II 
promoter, Wnt receptor 
signaling pathway 
 34 
 
CG10996 
galactose mutarotase (aldose 
1-epimerase) 
aldose 1-epimerase activity, 
carbohydrate binding 
hexose metabolic process 
Malic enzyme 
malic enzyme 1, NADP(+)-
dependent, cytosolic 
malate dehydrogenase 
(oxaloacetate-
decarboxylating) (NADP+) 
activity 
sleep, regulation of cell 
death, determination of adult 
lifespan 
Glyceraldehyde 
3 phosphate 
dehydrogenase 
1 
glyceraldehyde-3-phosphate 
dehydrogenase, 
spermatogenic 
glyceraldehyde-3-phosphate 
dehydrogenase (NAD+) 
(phosphorylating) activity, 
NAD binding, NADP 
binding 
glycolysis, oxidation-
reduction process 
CG4750 leucine aminopeptidase 3 
metalloexopeptidase 
activity, manganese ion 
binding, 
metalloexopeptidase activity 
proteolysis 
CG9413 
solute carrier family 7 
(cationic amino acid 
transporter, y+ system), 
member 9 
amino acid transmembrane 
transporter activity 
amino acid transmembrane 
transport 
cueball slit homolog 3 (Drosophila) 
Wnt-protein binding, Wnt-
activated receptor 
activity,low-density 
lipoprotein receptor activity 
primary spermatocyte 
growth 
CG15142 
cyclin-dependent kinase 2 
associated protein 1 
kinase activity 
nucleic acid binding 
protein binding 
kinase inhibitor activity 
kinase regulator activity 
DNA replication 
cellular protein modification 
process 
cell cycle 
cell communication 
regulation of catalytic 
activity 
 35 
 
Fat body protein 
2 
hydroxyprostaglandin 
dehydrogenase 15-(NAD) 
alcohol dehydrogenase 
(NAD) activity, nutrient 
reservoir activity 
oxidation-reduction process 
Trehalase 
trehalase (brush-border 
membrane glycoprotein) 
trehalase activity, 
alpha,alpha-trehalase 
activity 
trehalose metabolic process 
CG5955 
short chain 
dehydrogenase/reductase 
family 42E, member 1 
coenzyme binding, UDP-
glucose 4-epimerase activity 
cellular metabolic process 
Sarcoglycan 
alpha 
sarcoglycan, epsilon 
calcium ion binding, 
structural constituent of 
muscle 
unknown 
CG34380 neuropilin 2 
receptor signaling protein 
tyrosine kinase activity 
cell adhesion, signal 
transduction 
asparagine 
synthetase 
asparagine synthetase 
asparagine synthase 
(glutamine-hydrolyzing) 
activity 
asparagine biosynthetic 
process 
CG9847 
FK506 binding protein 11, 
19 kDa 
calcium ion binding, FK506 
binding, peptidyl-prolyl cis-
trans isomerase activity 
regulation of Notch signaling 
pathway, muscle cell cellular 
homeostasis,  
imaginal disc-derived wing 
margin morphogenesis, 
imaginal disc  
development, chaeta 
development 
CG18599 intestine-specific homeobox 
sequence-specific DNA 
binding transcription factor 
activity, sequence-specific 
DNA binding 
regulation of transcription, 
DNA-dependent 
Cytochrome c 
proximal 
cytochrome c, somatic electron carrier activity oxidative phosphorylation 
CG31454 transmembrane protein 135 unknown unknown 
 36 
 
SP1029 
alanyl (membrane) 
aminopeptidase 
zinc ion binding, 
metallopeptidase activity, 
aminopeptidase activity 
lateral inhibition, proteolysis 
Gliotactin butyrylcholinesterase carboxylesterase activity 
synaptic target recognition, 
border follicle cell 
migration,cell adhesion 
involved in heart 
morphogenesis,establishment 
of blood-nerve barrier,female 
meiosis chromosome 
segregation, maintenance of 
imaginal disc-derived wing 
hair orientation, regulation of 
tube size, open tracheal 
system, 
CG5665 lipase, member H lipase activity lipid catabolic processes 
CG9485 
amylo-1, 6-glucosidase, 4-
alpha-glucanotransferase 
4-alpha-glucanotransferase 
activity,  amylo-alpha-1,6-
glucosidase activity 
glycogen catabolic process,  
glycogen biosynthetic 
process 
Putative 
glycogen 
[starch] 
synthase 
glycogen synthase 1 (muscle) 
glycogen (starch) synthase 
activity 
glycogen biosynthetic 
process 
CG30281 fibrinogen gamma chain receptor binding 
cell communication 
cell-matrix adhesion 
cell-cell adhesion 
CG6658 
UDP glucuronosyltransferase 
2 family, polypeptide B15 
glucuronosyltransferase 
activity 
metabolic process 
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Table A2-1: Transgenic RNAi stocks for genes with no Act5C-Gal4 phenotype 
Gene: Stock#:  Gene: Stock#: 
Netrin-B BL25861, BL34698  CG34420 BL53932 
CG11153 BL26220  CG11546 BL53349 
CG18480 BL28529  CG10833 BL53892 
CG9108 BL28574  CG31092 BL54461 
CG34392 BL29217  CG5002 BL55359 
CG31092 BL31150  ImpL2 BL55855 
yolkless BL31152  CG4666 BL55939 
wunen-2 BL32382, BL32423  CG9416 V106330 
Sarcoglycan 
alpha 
BL34027  Tim17a1 V101139 
CG9485 BL34333  CG15731 V30244, V30246 
CG4415 BL35613  Nidogen V109625 
CG5665 BL35717  CG7432 V31091 
asparagine 
synthetase 
BL35739  CG4438 V105175 
cueball BL36875  CG10859 V27322 
Malic 
enzyme 
BL38256, BL41652  CG12389 V104362 
quail BL41856  CG7890 V110601 
CG13838 BL42898  tenectin V42326 
CG1544 BL43310  CG15286 V106518 
Fbp2 BL44052, BL50545  CG3777 V109678 
CG34380 BL44089  CG10996 V104158 
CG15556 BL44574  CG9847 
V12863, V12864, 
V39071 
CG16869 BL50691  CG31454 V5811 
CG34372 BL51472  CG6904 V35136,V35137 
CG9413 BL51791  CG30281 V108551 
CG13320 BL51829  CG6658 V104262 
CanA-14F V109858    
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Table A2-2: Transgenic RNAi Stock and cross data for genes with Act5C-Gal4 
phenotypes 
Gene: Stock # 
Act5C-
Gal4 
En-Gal4 69B-Gal4 71B-Gal4 Vn-Gal4 
G protein 
gamma30a 
BL 25932 
Pharate 
Lethal 
No 
Phenotype 
No Phenotype No Phenotype No Phenotype 
BL 34484 
Larval 
Lethal 
29°C – 
Larval 
Lethal 
29°C – Larval 
Lethal 
29°C – Pharate Lethal 
29°C – Larval 
Lethal 
25°C – 
Larval 
Lethal 
25°C – Larval 
Lethal 
25°C – 1/3 have extra 
veins between L2 + 
L3, below L4 and on 
PCV. Also pharate 
lethal 
25°C – Pharate 
Lethal 
17°C – 
Extra veins 
on PCV and 
L5 
17°C – 2/2 
extra wing 
veins on L2, 
L3, and PCV; 
pupal lethal 
17°C – 23/43 have 
extra veins between 
L2 + L3 and on PCV 
17°C – Pharate 
Lethal 
SoxNeuro BL25996 
Larval 
Lethal 
No 
Phenotype 
No Phenotype 
4/38 -wrinkled wings, 
5/38 – extra vein 
below L3 
No Phenotype 
CG34396 BL26011 
Pharate 
Lethal 
29°C – 
Pharate 
Lethal No Phenotype No Phenotype 
21/49 – No 
ACV 
25°C - No 
Phenotype 
Enolase 
BL26300 
Larval 
Lethal 
No 
Phenotype 
No Phenotype No Phenotype 
29°C – Lethal 
25°C – No 
Phenotype 
17°C – No 
Phenotype 
BL41467 
Larval 
Lethal 
No 
Phenotype 
No Phenotype 
38/86 – spots of dark 
pigment on wing 
margins, especially 
below L4 and L5 
No Phenotype 
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Gapdh2 26302 
Larval 
Lethal 
29°C – 
Lethal 
29°C – 7/28 
have extra vein 
on PCV, some 
pharates 
29°C – 3/27 have 
extra vein below L3, 
some pharate lethal 
29°C – Lethal 
25°C –
Lethal 
25°C – No 
Phenotype 
25°C –No Phenotype, 
some pharate lethal 
25°C – Lethal  
17°C – No 
Phenotype 
17°C – No 
Phenotype 
17°C – No Phenotype 
17°C – No 
Phenotype 
tpi 26304 
Pharate 
Lethal 
No 
Phenotype 
No Phenotype No Phenotype 
4/40 missing 
ACV 
1/40 missing 
part of PCV 
CG9411 28320 
Pharate 
Lethal 
No 
Phenotype 
No Phenotype No Phenotype No Phenotype 
Ccn BL31715 
Larval 
Lethal 
29°C – 
Larval 
Lethal 
No Phenotype No Phenotype 
20/21 have no 
ACV and fold 
in wing 
between L3 and 
L4 
25°C –
Pharate 
Lethal 
17°C – 
28/31 have 
smaller 
wings from 
L4 down 
and no PCV 
Gliotactin BL31869 
Larval 
Lethal 
8/10 have 
no ACV and 
wrinkled 
wings 
29°C – 6/6 
have wrinkled 
wings, some 
pharates 
14/30 curly wings, 
13/30  curly and 
wrinkled wing 
Curly wings 
25°C – 62/62 
have wrinkled 
wings 
17°C – 56/56 
have fold 
between L3 and 
L4 
ImpL3 BL33640 
Low 
Viability 
No 
Phenotype 
No Phenotype No Phenotype 
3/47 have 
wrinkled wings 
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Hsp70Bbb BL33916 Larval 
Lethal 
No 
Phenotype 
29°C – Lethal No Phenotype No Phenotype 
25°C – No 
Phenotype 
CG12009 BL41968 
Larval 
Lethal 
22/27 – 
smaller 
wings, no 
ACV 
24/28 – smaller 
wings, region 
between L2 and 
L3 smaller 
No Phenotype 
13/13 – smaller 
wing, missing 
part of L3 and 
ACV 
Trehalase 
BL50585 
Larval 
Lethal 
No 
Phenotype 
No Phenotype No Phenotype No Phenotype 
BL51810 
Larval 
Lethal 
No 
Phenotype 
No Phenotype 
2/49 – extra vein on 
PCV 
No Phenotype 
loopin-1 BL54012 
Larval 
Lethal 
No 
Phenotype 
29°C – Low 
viability (74 
CyO/5 RNAi) No Phenotype 
29°C – Lethal 
25°C – No 
Phenotype  
25°C – Lethal 
17°C – Lethal 
CG32238 BL54016 
Larval 
Lethal 
2/20 – extra 
vein below 
L3 
No Phenotype 1/37 – blistered wing 6/41 – no ACV 
SP1029 V1065785 
Pharate 
Lethal 
31/59 – 
extra wing 
vein on 
PCV and 
below L4 
No Phenotype 2/98 – wrinkled wings 
29°C – Lethal 
25°C – Lethal 
17°C – Lethal 
Wnt 
oncogene 
analog 2 
BL36722 
Held 
Wings 
Out 
No 
Phenotype 
29°C –30/30 
held wings out 
No Phenotype No Phenotype 
25°C – 26/26 
held wings out 
BL44271 
Held 
Wings 
Out 
No 
Phenotype 
No Phenotype No Phenotype No Phenotype 
CG15731 
v30244 
No 
Phenotype 
No 
Phenotype 
47/61 Extra 
vein above L2 
No Phenotype No Phenotype 
v30246 
Pharate 
Lethal 
No 
Phenotype 
12/40 Extra 
vein above L2, 
some pharates 
No Phenotype No Phenotype 
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CG14968 v102790 
Pharate 
Lethal 
4/38 no 
ACV 
19/21 - not 
inflated wings 
No Phenotype 
17/42 - pigment 
on wings, held 
wings out,           
25/42 - held 
wings out 
elF4E-5 v102173 
Pharate 
Lethal 
No 
Phenotype 
No Phenotype No Phenotype No Phenotype 
stall v104737 
Pharate 
Lethal 
10/56 - dark 
pigment on 
wing                       
3/56  - 
smaller 
wing L3 
down 
Pharate lethal No Phenotype No Phenotype 
mnd v110217 
Pharate 
Lethal 
No 
Phenotype 
36/71 Extra 
vein between 
L3/L4 
No Phenotype No Phenotype 
CG32512 v32904 
Larval 
Lethal 
Lethal, 3/4 
missing 
ACV 
Pharate Lethal Pharate lethal Pharate Lethal 
CG14309 v103061 
Pharate 
Lethal 
No 
Phenotype 
Pharate lethal No Phenotype No Phenotype 
CG31689 v102097 
Pharate 
Lethal 
11/11 - 
small wings, 
ACV loss, 
"serrate" 
like 
No Phenotype No Phenotype 26/32 - no ACV 
CG11652 v103550 
Pharate 
Lethal 
20/23 - 
smaller 
wing L4 
down, no 
ACV 
No Phenotype No Phenotype No Phenotype 
pathetic v100519 
Pharate 
Lethal 
No 
Phenotype 
37/54 - un-
inflated wings 
No Phenotype No Phenotype 
nxf4 v101011 
Pharate 
Lethal 
65/72 - 
smaller 
wing from 
L3 down, no 
ACV 
Pharate lethal No Phenotype No Phenotype 
CG34107 v109592 
Pharate 
Lethal 
25/25 - 
pigment on 
wings 
29°C – Pharate 
lethal             
17°C – 23/101 
un-inflated 
wings 
No Phenotype 
35/35 wrinkled 
wing 
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CG18173 v105262 
Pharate 
Lethal 
27/51 - 
smaller 
wing L3 
down                       
24/51 - 
smaller 
wing L3 
down, no 
ACV 
No Phenotype No Phenotype No Phenotype 
nemy 
v7909 
Pharate 
Lethal 
No 
Phenotype 
18/83 - Extra 
vein above L2 
No Phenotype No Phenotype 
v40803 
No 
Phenotype 
No 
Phenotype 
30/95 - Extra 
vein above L2 
No Phenotype No Phenotype 
CG15478 v103025 
Pharate 
Lethal 
46/46 - 
pigment on 
wings 
29°C – Pharate 
lethal, 2/6 
adults have 
small, 
uninflated 
wings                      
17°C – No 
Phenotype 
No Phenotype No Phenotype 
Mipps1 v101634 
Larval 
Lethal 
(Male 
lethal) 
39/39 - 
below L3 
almost gone 
No Phenotype No Phenotype No Phenotype 
CG6330 v104776 
Pharate 
Lethal 
No 
Phenotype 
No Phenotype No Phenotype No Phenotype 
CG16957 v105897 
Larval 
Lethal 
No 
Phenotype 
No Phenotype No Phenotype No Phenotype 
CG15142 v104998 
Pharate 
Lethal 
No 
Phenotype 
Pharate Lethal No Phenotype No Phenotype 
CG5955 v102443 
Pharate 
Lethal 
Larval 
Lethal 
Pharate lethal No Phenotype No Phenotype 
CG18599 v110312 
Pharate 
Lethal 
No 
Phenotype 
30/92 Extra 
vein above L2 
7/35 - Extra vein 
above L2               
No Phenotype 
Cyt-c-p v106759 
Larval 
Lethal 
Pupal Lethal No Phenotype No Phenotype No Phenotype 
CG8483 BL58094 
Larval 
Lethal 
27/27 
smaller 
wing L3 
down                        
4/27 no 
ACV 
2/2 Low 
Viability, No 
Phenotype 
No Phenotype 17/18 no ACV 
*All crosses done at 29°C, unless noted    
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Appendix 3: 
Analysis of CG4096, a known negative regulator of Egfr signaling 
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Further investigation of CG4096, a negative regulator of Egfr signaling 
CG4096 expression was identified as a candidate gene upregulated in the presence of drug 
inducible RasV12 in this study.  A previous study in our lab has shown that CG4096 is a negative 
regulator of Egfr signaling (upstream of Ras) and it has been empirically shown that CG4096 is 
operating on the same level as the Egfr ligands (Figure 10, Butchar et al. 2012).  CG4096 encodes 
an ADAMTS (A Dysintegrin and A Metalloproteinase with Thrombospondin Motif) protein.  
ADAMTS proteins in humans have been implicated in cancer, and ADAMTS1 and -15, the human 
orthologs of CG4096, have been shown to affect EGF ligands (Porter et al. 2006 and Wagstaff et 
al. 2011). I have conducted additional analysis in order to further characterize CG4096’s role in 
Egfr signaling. 
First, I attempted to create a fly carrying a knock-out mutation of CG4096.  Previously, an 
undergraduate in the Simcox lab tried to conduct a P-element excision using a transgenic fly 
carrying a P-element insertion in CG4096 (CG4096EPgy2) (Figure 1A). The excision of the P-
element was successful (data not shown). However, the resulting mutation was hemizygous lethal 
- CG4096 is located on the X chromosome.  I performed complementation tests using transgenic 
flies carrying 100kb translocation/duplications of the X chromosome (Figure 1) which failed to 
complement the CG4096ΔEPgy2 mutation. 
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Second, we used the CRISPR-Cas9 system to generate the CG4096 mutant. CRISPR 
(Clustered Regularly Interspaced Short Palindromic Repeats) is a system developed from a 
bacterial immunological defense system used to target specific genes, while Cas9 is the protein 
that mediates the targeting and excision (Richter et al. 2012).  First, we designed a guide sequence 
to target CG4096 and tested it in vitro using Cas9-expressing Ras-attP-L1 cells generated in our 
lab using site-specific RMCE (Figure 2). 
𝐶𝐺4096∆𝐸𝑃𝑔𝑦2
𝐹𝑀7
; ; 
+
𝑦
; ;
 Dp(1; 3)DC141
 Dp(1; 3)DC141
 X 
𝐶𝐺4096∆𝐸𝑃𝑔𝑦2
𝑦
; ;
 Dp(1; 3)DC141
 +
 
B 
C 
Figure 1: (A) Map of the EPgy2 P-element insertion in CG4096 
(B) Crossing scheme for complementation test of CG4096ΔEPgy2 
(C) X chromosome map of deletion stocks used for 
complementation test 
A 
CG4096 
P{EPgy2}CG4096
EY02397
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After confirmation of the efficacy of our guide sequence (Figure 3), I moved to generate a 
mutation in vivo.  I chose to use two guide sequences (one targeting CG4096 and the other targeting 
the mini white marker) to generate a large deletion and to simplify mutant screening, as a fly 
carrying the correct deletion will have white eyes.  The injection mixture was prepared as described 
in Materials and Methods, and injected into CG4096EPgy2 flies. The injection mixture was prepared 
of four separate plasmids containing the following constructs, respectively: Act-Gal4, UAS-Cas9-
SV40, and CRISPR plasmids (U6-SgRNA) targeting CG4096 and w separately, and was injected 
Figure 2: A Ras-attP-L1 cell line expressing a GFP-tagged Cas9 gene was generated using the 
RMCE protocol described in Manivannan et al. 2015.  Western blot analysis shows the fusion 
protein being expressed at the correct size.  These Cas9-expressing cells were transfected with 
a plasmid encoding a guide RNA targeting the CG4096 gene.  SURVEYOR analysis showed 
cleavage at the target size; a scrambled guide sequence control (SC) had no effect. 
(adapted from Manivannan et al. 2015) 
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into CG4096EPgy2 flies. Unfortunately, several attempts at generating this mutant fly failed.  One 
known culprit of the low efficiency of the system in whole flies compared to cell cultures is the 
use of plasmids and the requirement that transcription occurs for all components to successfully 
generate of a deletion.  New studies show improved methods using the CRISPR/Cas9 system to 
create deletions in flies. Notably, CRISPR guide RNAs are injected into transgenic flies with Cas9 
under vasa or nanos promoters, which allows germline expression of the enzyme (Gratz et al. 
2015). 
Finally, during my work on a genome-wide tumor suppressor screen in L.S. Shashidhara’s 
Lab, I found that CG4096 cooperates with yorkie (yki), a member of the Hippo signaling pathway, 
to generate tumor-like wing disc growth.  The Hippo pathway controls organ size by regulating 
cell proliferation and apoptosis, and defects in this pathway have been implicated in human cancers 
(Zhao, B. et al. 2007).  Co-expression of CG4096 RNAi and yki (a positive regulator of the Hippo 
pathway), generated large tumorous wing discs in third instar larvae (Figure 4). Interestingly, co-
expression of CG4096 RNAi and Egfr did not show this same phenotype, even though it has been 
previously shown that CG4096 interacts with Egfr (Figure 4, Butchar et al. 2012).  I then looked 
at the cell polarity these wing discs, as loss of epithelial cell polarity can lead to metastasis of 
cancer (Li et al. 2015 and Lee and Vasioukhin 2008).  However, cell polarity of actin is not lost in 
ap > yki, CG4096RNAi wing discs (Figure 4D). It is evident that CG4096 has a role in both the Egfr 
and Hippo signaling pathways, warranting further analysis into its molecular functions in 
Drosophila.  
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A B 
C 
D 
Figure 11: (A) 3rd instar larvae with GFP indicating wing disc 
size: ap > yki, GFP (top left) shows modest overgrowth, ap > 
yki, PTENRNAi and ap > yki, CG4096RNAi (top right and bottom 
right) show massive overgrowth, and ap > Egfr, CG4096RNAi 
(bottom left) shows no overgrowth (B-D) Confocal 
micrographs of 3rd instar wing discs of the following genotypes: 
(B) ap > yki, GFP, (C) ap > yki, CG4096RNAi and (D) ap > 
CG4096RNAi (top) and ap > yki, CG4096RNAi (bottom), with 
insets showing optical cross-section to visualize actin polarity. 
(L. S. Shashidhara lab, unpublished) 
